Drug Profile
P 882284
Latest Information Update: 31 Jan 2008
Price :
$50
*
At a glance
- Originator Nissan Chemical Industries
- Class
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 10 Jun 1998 New profile
- 10 Jun 1998 Suspended-Preclinical for Hyperlipidaemia in Japan (Unknown route)